HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Related Collections Related Articles

April 10 Highlights

Jacoby et al. compared quality of life outcomes between patients with new-onset seizures who received either immediate or delayed antiepileptic medication. The findings, based on 331 individuals, suggest no significant advantage of starting treatment immediately, with the single exception of driving status.

see page 1188

There is an accompanying editorial by Barbara Vickrey.

see page 1172

¹¹C-PIB PET distinguishes AD from FTLD

Rabinovici et al. found that 7 out of 7 patients with AD had elevated cortical uptake of the Aß PET ligand ¹¹C-PIB, while 8 out of 12 patients with frontotemporal lobar degeneration had negative scans. ¹¹C-PIB may have an important role in the differential diagnosis of dementia.

see page 1205

Nocturnal blood pressure in restless legs syndrome

Pennestri et al. found significant increase in systolic (<22 mm Hg) and diastolic (<11 mm Hg) blood pressure in association with periodic leg movements during sleep in subjects with restless legs syndrome. Blood pressure changes were greater when the movements were associated with EEG signs of arousal.

see page 1213

Retigabine, a novel antiepileptic drug, demonstrates efficacy in a controlled, clinical trial

The development of agents that enhance potassium currents through K± channels has long been the aim of scientists seeking new ways to stop seizures in patients with epilepsy. Retigabine is the most advanced of these compounds. Porter et al. evaluated 399 randomized patients with partial seizures in a Phase 2 RCCT study. The authors found that retigabine decreased seizure frequency in a dose-response manner. The drug also improved responder rates. Retigabine is the first drug of this type to reach this stage of clinical development. A Phase 3 program is ongoing.

see page 1197

Predicting a successful treatment in PC-BPPV

Oh et al. examined the nystagmus during the second position of the Epley maneuver in126 patients with PC-BPPV. The finding of torsional upbeating nystagmus in the same direction as that seen during the first position of the Hallpike maneuver (orthotropic nystagmus) predicted a successful repositioning, while the finding of either reversed or no nystagmus predicted a treatment failure. This may differentiate between canalolithiasis and cupulolithiasis.

see page 1219

Tapping the head tests the vestibulo-ocular reflex

Iwasaki et al. extend the understanding of central vestibular physiology (specifically extraocular vestibular evoked myogenic potentials) through studies on forehead tapping.

see page 1227

Related Articles

When the patient knows best: A challenge in translating clinical trial evidence into practice

Barbara G. Vickrey
Neurology 2007 68: 1172-1173. [Full Text] [PDF]

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Related Collections Related Articles